Sun Pharmaceutical Industries Ltd

Go Back

Sun Pharmaceutical Industries Ltd

  • Among the top five Indian pharma companies
  • Strong presence in generics market
  • Over half the sales from North America
  • Market capitalization of US$ 15.6 billion
  • Revenue base of about US$ 2.1 billion

Sun Pharmaceutical Industries Ltd


Sun Pharmaceutical Industries Ltd is an international specialty pharma company. The Company manufactures and markets pharmaceuticals formulations as branded generics, as well as generics in India, the United States (US) and several other markets across the world.

The Company’s business is divided into four segments: Indian Branded Generics, US Generics, International Branded Generics (ROW) and Active Pharmaceutical Ingredients (API).

Its brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory. It makes specialty APIs, including peptides, steroids, hormones and anticancers. APIs and Dosage forms are made at 20 plants across India, Israel, the US, Canada, Hungary, Brazil, Mexico and Bangladesh. Its API products include Acamprosate Calcium, Alendronate Sodium, Amifostine trihydrate, Budensonide and Carvedilol.

In September 2010, it acquired Taro Pharmaceutical industries Ltd.

Source: http://www.sunpharma.com/

Sun Pharma: Leveraging its generic market capabilities

1983 Commenced operations in Kolkata
1987 Nationwide marketing operations rolled out
1995 Built the first API plant
2004 First international acquisition: Niche Brand in the US
2012 Acquired controlling stake in Taro and full control on Caraco

Updated: August, 2013

Pharmaceuticals
India's pharmaceutical sector will touch US$ 45 billion by 2020.
x IBEF : India Brand Equity Foundation